Royalty Pharma (RPRX) Total Debt (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Total Debt data on file, last reported at $9.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 22.57% year-over-year to $9.3 billion; the trailing twelve-month figure through Mar 2026 stood at $9.3 billion (up 22.57% YoY), and the FY2025 full-year result was $9.3 billion, up 8.37% from the prior year.
• Total Debt was little changed at $9.3 billion in Q1 2026, from $9.3 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $9.3 billion in Q1 2026 to a low of $6.1 billion in Q3 2023.
• A 5-year average of $7.7 billion and a median of $7.6 billion in 2024 frame the typical range for Total Debt.
• Peak annual rise in Total Debt reached 40.34% in 2024, while the deepest fall reached 24.39% in 2024.
• Tracing RPRX's Total Debt over 5 years: stood at $7.1 billion in 2022, then fell by 13.79% to $6.1 billion in 2023, then soared by 40.34% to $8.6 billion in 2024, then increased by 8.37% to $9.3 billion in 2025, then grew by 0.06% to $9.3 billion in 2026.
• Business Quant data shows RPRX's Total Debt at $9.3 billion in Q1 2026, $9.3 billion in Q4 2025, and $8.9 billion in Q3 2025.